Literature DB >> 21800837

The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket.

Nootan Pandey1, Chaturbhuj A Mishra, Dinesh Manvar, Alok K Upadhyay, Tanaji T Talele, Thomas W Comollo, Neerja Kaushik-Basu, Virendra N Pandey.   

Abstract

Earlier, we postulated that Gln91 of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) stabilizes the side chain of Tyr183 via hydrogen bonding interaction between O(H) of Tyr183 and CO of Q91 [Harris, D., et al. (1998) Biochemistry 37, 9630-9640]. To test this hypothesis, we generated mutant derivatives of Gln91 and analyzed their biochemical properties. The efficiency of reverse transcription was severely impaired by nonconservative substitution of Gln with Ala, while conservative substitution of Gln with Asn resulted in an approximately 70% loss of activity, a value similar to that observed with the Y183F mutation. The loss of polymerase activity from both Q91A and Q91N was significantly improved by a Met to Val substitution at position 184. Curiously, the Q91N mutant exhibited stringency in discriminating between correct and incorrect nucleotides, suggesting its possible interaction with residues influencing the flexibility of the dNTP binding pocket. In contrast, both double mutants, Q91A/M184V and Q91N/M184V, are found to be as error prone as the wild-type enzyme. We propose a model that suggests that subtle structural changes in the region due to mutation at position 91 may influence the stability of the side chain of Tyr183 in the catalytic YMDD motif of the enzyme, thus altering the active site geometry that may interfere in substrate recognition.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800837      PMCID: PMC3204787          DOI: 10.1021/bi200815e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  63 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  S F Chao; V L Chan; P Juranka; A H Kaplan; R Swanstrom; C A Hutchison
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

3.  Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.

Authors:  B Canard; S R Sarfati; C C Richardson
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

4.  Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  M Gutiérrez-Rivas; A Ibáñez; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  J Mol Biol       Date:  1999-07-16       Impact factor: 5.469

5.  Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization.

Authors:  M Ghosh; P S Jacques; D W Rodgers; M Ottman; J L Darlix; S F Le Grice
Journal:  Biochemistry       Date:  1996-07-02       Impact factor: 3.162

6.  The fidelity of 3' misinsertion and mispair extension during DNA synthesis exhibited by two drug-resistant mutants of the reverse transcriptase of human immunodeficiency virus type 1 with Leu74-->Val and Glu89-->Gly.

Authors:  T Rubinek; M Bakhanashvili; R Taube; O Avidan; A Hizi
Journal:  Eur J Biochem       Date:  1997-07-01

7.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

8.  Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.

Authors:  E J Arts; X Li; Z Gu; L Kleiman; M A Parniak; M A Wainberg
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

9.  Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

Authors:  G Tachedjian; J Mellors; H Bazmi; C Birch; J Mills
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

View more
  1 in total

1.  A Novel Leu92 Mutant of HIV-1 Reverse Transcriptase with a Selective Deficiency in Strand Transfer Causes a Loss of Viral Replication.

Authors:  Eytan Herzig; Nickolay Voronin; Nataly Kucherenko; Amnon Hizi
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.